CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Recurrent oropharyngeal squamous cell carcinomas maintain anti-tumor immunity and multinucleation levels following completion of radiation.
Recurrent oropharyngeal squamous cell carcinomas maintain anti-tumor immunity and multinucleation levels following completion of radiation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
口咽鳞状细胞癌(OPSCC)复发几乎普遍致命。开发有效的治疗选择需要更深入地了解复发性OPSCC的生物学。
我们分析了2000年至2020年间在Michael E. DeBakey退伍军人事务医疗中心接受治疗的退伍军人中配对的原发-复发性OPSCC,这些患者接受了根治性放疗为基础的治疗(伴或不伴化疗)。使用标准免疫组织化学和浸润淋巴细胞及多核肿瘤细胞的自动成像结合机器学习算法对患者肿瘤进行分析。
原发肿瘤和复发肿瘤通过p16和p53免疫组化显示出高度一致性,多核化水平相当。相比之下,复发肿瘤显示出显著更高水平的CD8+TIL(肿瘤浸润淋巴细胞)(p<0.05)和更高水平的PD-L1表达(p<0.05)。
暴露于放化疗以及治疗后复发似乎不会对口咽癌的潜在生物学特征和抗肿瘤免疫产生不利影响,提示新型治疗方案在挽救治疗情境下可能与其在根治性治疗情境下同样有效。
Oropharyngeal squamous cell carcinoma (OPSCC) recurrence is almost universally fatal. Development of effective therapeutic options requires an improved understanding of recurrent OPSCC biology.
We analyzed paired primary-recurrent OPSCC from Veterans treated at the Michael E. DeBakey Veterans Affairs Medical Center between 2000 and 2020 who received curative intent radiation-based treatment (with or without chemotherapy). Patient tumors were analyzed using standard immunohistochemistry and automated imaging of infiltrating lymphocytes and multinucleated tumor cells coupled to machine learning algorithms.
Primary and recurrent tumors demonstrated high concordance via p16 and p53 immunohistochemistry, with comparable levels of multinucleation. In contrast, recurrent tumors demonstrated significantly higher levels of CD8+ tumor infiltrating lymphocytes (p<0.05) and higher levels of PD-L1 expression (p<0.05).
Exposure to chemo-radiation and recurrence following treatment does not appear deleterious to underlying biological characteristics and anti-tumor immunity of oropharyngeal cancer, suggesting that novel treatment regimens may be as effective in the salvage setting as in the definitive intent setting.
MEMBER ACCOUNT
登录成功会直接打开下一页。